A. Ceribelli

2.0k total citations · 1 hit paper
27 papers, 1.7k citations indexed

About

A. Ceribelli is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, A. Ceribelli has authored 27 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 4 papers in Neurology. Recurrent topics in A. Ceribelli's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (8 papers). A. Ceribelli is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Research Studies (8 papers). A. Ceribelli collaborates with scholars based in Italy, United States and Malaysia. A. Ceribelli's co-authors include Giorgio V. Scagliotti, M. Marangolo, Filippo de Marinis, Serafino Ricci, Lucio Crinò, Monica Rinaldi, Francesco Di Costanzo, Maurizio Tonato, Cesare Gridelli and Vincenzo Adamo and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

A. Ceribelli

27 papers receiving 1.6k citations

Hit Papers

Phase III Randomized Trial Comparing Three Platinum-Based... 2002 2026 2010 2018 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
    2002 739 citations Giorgio V. Scagliotti, Filippo de Marinis et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Ceribelli Italy 10 1.3k 1.1k 276 218 139 27 1.7k
Jean Louis Pujol France 16 1.3k 1.0× 1.1k 1.0× 281 1.0× 140 0.6× 123 0.9× 35 1.8k
Nadia Chouaki France 19 1.3k 1.0× 1.3k 1.1× 226 0.8× 200 0.9× 210 1.5× 48 1.7k
Keita Kudo Japan 13 611 0.5× 1.0k 0.9× 173 0.6× 122 0.6× 107 0.8× 35 1.3k
Do Hyoung Lim South Korea 15 642 0.5× 725 0.6× 202 0.7× 365 1.7× 126 0.9× 39 1.1k
N. Androulakis Greece 20 681 0.5× 1.1k 1.0× 236 0.9× 182 0.8× 290 2.1× 46 1.3k
Xinmin Yu China 18 704 0.5× 746 0.7× 193 0.7× 112 0.5× 217 1.6× 48 1.1k
Aris Polyzos Greece 19 607 0.5× 1.2k 1.1× 229 0.8× 267 1.2× 262 1.9× 55 1.5k
Claudio Dazzi Italy 17 494 0.4× 556 0.5× 220 0.8× 154 0.7× 211 1.5× 57 982
Akito Hata Japan 25 1.4k 1.1× 1.1k 0.9× 320 1.2× 111 0.5× 325 2.3× 117 1.7k
Nina Karaseva Russia 12 759 0.6× 948 0.8× 339 1.2× 86 0.4× 156 1.1× 20 1.3k

Countries citing papers authored by A. Ceribelli

Since Specialization
Citations

This map shows the geographic impact of A. Ceribelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Ceribelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Ceribelli more than expected).

Fields of papers citing papers by A. Ceribelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Ceribelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Ceribelli. The network helps show where A. Ceribelli may publish in the future.

Co-authorship network of co-authors of A. Ceribelli

This figure shows the co-authorship network connecting the top 25 collaborators of A. Ceribelli. A scholar is included among the top collaborators of A. Ceribelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Ceribelli. A. Ceribelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Isailovic, Natasa, et al.. (2025). Antinuclear antibodies target unknown autoantigens in porto-sinusoidal vascular disorder (PSVD) without portal hypertension. Digestive and Liver Disease. 57. S35–S35. 1 indexed citations
2.
Maïo, Massimo Di, Maria Carmela Piccirillo, Gennaro Daniele, et al.. (2014). Symptomatic Toxicities Experienced During Anti-Cancer Treatment: Comparison of Patients' and Physicians' Reporting in Three Randomized Controlled Trials (Rcts). Annals of Oncology. 25. iv517–iv517. 1 indexed citations
3.
Bria, Emilio, Michèle Milella, Federica Cuppone, et al.. (2011). Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Annals of Oncology. 22(10). 2277–2285. 81 indexed citations
4.
Maïo, Massimo Di, Alessandro Morabito, Santi Barbera, et al.. (2010). Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials.. Journal of Clinical Oncology. 28(15_suppl). 6124–6124. 1 indexed citations
5.
Palmieri, Giovannella, Piera Federico, Mirella Marino, et al.. (2009). Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Annals of Oncology. 21(6). 1168–1172. 46 indexed citations
6.
Ceresoli, Giovanni Luca, B. Castagneto, Paolo Andrea Zucali, et al.. (2008). Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. British Journal of Cancer. 99(1). 51–56. 78 indexed citations
7.
Bria, Emilio, A. Ceribelli, Marco Trovò, et al.. (2006). Non-small cell lung cancer: early stages. Annals of Oncology. 17. ii17–ii21. 2 indexed citations
8.
Maio, Marco Di, Ciro Gallo, A. Ceribelli, et al.. (2006). Two-drug gemcitabine-based first-line treatment of elderly patients (pts) with small cell lung cancer (SCLC): The G-STEP program. Journal of Clinical Oncology. 24(18_suppl). 7089–7089. 2 indexed citations
9.
Milella, Michèle, Paolo Carlini, Alain Gelibter, et al.. (2006). Gemcitabine-based polychemotherapy for advanced pancreatic cancer (APC): Is it ready for prime time? A pooled analysis of 3,682 patients (pts) enrolled in 12 phase III trials. Journal of Clinical Oncology. 24(18_suppl). 4118–4118. 4 indexed citations
10.
Bria, Emilio, Paolo Carlini, Alain Gelibter, et al.. (2006). Current status of targeted agents in advanced pancreatic cancer (APC): A pooled analysis of 2,361 patients (pts) enrolled in six phase III trials. Journal of Clinical Oncology. 24(18_suppl). 4126–4126. 4 indexed citations
11.
Cappuzzo, Federico, Silvia Novello, Filippo de Marinis, et al.. (2005). Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. British Journal of Cancer. 93(1). 29–34. 27 indexed citations
12.
Parrà, Héctor Soto, Paolo Andrea Zucali, Adolfo Favaretto, et al.. (2005). P-428 A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM). Lung Cancer. 49. S228–S228. 1 indexed citations
13.
Milella, Michèle, A. Ceribelli, Alain Gelibter, et al.. (2005). Celecoxib combined with fixed dose-rate gemcitabine (FDR-Gem)/CDDP as induction chemotherapy for stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7324–7324. 1 indexed citations
14.
Gridelli, Cesare, Ciro Gallo, Massimo Di Maïo, et al.. (2004). A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer. 91(12). 1996–2004. 143 indexed citations
15.
Fabi, Alessandra, Virginia Ferraresi, Enrico Cortesi, et al.. (2004). The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.. PubMed. 23(1). 25–32. 5 indexed citations
16.
Gelibter, Alain, A. Ceribelli, Michèle Milella, et al.. (2003). Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.. PubMed. 22(3). 481–5. 5 indexed citations
17.
Crinò, Lucio, Giorgio V. Scagliotti, Serafino Ricci, et al.. (1999). Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project. Journal of Clinical Oncology. 17(11). 3522–3530. 302 indexed citations
18.
Baldini, Editta, Carmelo Tibaldi, E. Pfanner, et al.. (1996). Phase II Study of Oral Doxifluridine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 19(6). 592–594. 9 indexed citations
19.
Falcone, Alfredo, E. Pfanner, Serafino Ricci, et al.. (1994). Oral doxifluridine in elderly patients with metastatic colorectal cancer: A multicenter phase II study. Annals of Oncology. 5(8). 760–762. 29 indexed citations
20.
Pollera, C. F., A. Ceribelli, M Crecco, & F. Calabresi. (1994). Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Annals of Oncology. 5(2). 182–184. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean Louis Pujol Breakdown of academic impact, for papers by Nadia Chouaki Breakdown of academic impact, for papers by Keita Kudo Breakdown of academic impact, for papers by Do Hyoung Lim Breakdown of academic impact, for papers by N. Androulakis Breakdown of academic impact, for papers by Xinmin Yu Breakdown of academic impact, for papers by Aris Polyzos Breakdown of academic impact, for papers by Claudio Dazzi Breakdown of academic impact, for papers by Akito Hata Breakdown of academic impact, for papers by Nina Karaseva
Rankless by CCL
2026